NO951219L - Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav - Google Patents
Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling deravInfo
- Publication number
- NO951219L NO951219L NO951219A NO951219A NO951219L NO 951219 L NO951219 L NO 951219L NO 951219 A NO951219 A NO 951219A NO 951219 A NO951219 A NO 951219A NO 951219 L NO951219 L NO 951219L
- Authority
- NO
- Norway
- Prior art keywords
- plasminogen
- blood clots
- liposomes
- preparation
- treatment
- Prior art date
Links
- 208000007536 Thrombosis Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000013566 Plasminogen Human genes 0.000 abstract 6
- 108010051456 Plasminogen Proteins 0.000 abstract 6
- 239000002502 liposome Substances 0.000 abstract 4
- 102000001938 Plasminogen Activators Human genes 0.000 abstract 3
- 108010001014 Plasminogen Activators Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229940127126 plasminogen activator Drugs 0.000 abstract 3
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Actuator (AREA)
- Structures Of Non-Positive Displacement Pumps (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9201722A NL9201722A (nl) | 1992-10-05 | 1992-10-05 | Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan. |
| PCT/NL1993/000195 WO1994007537A1 (en) | 1992-10-05 | 1993-10-05 | Pharmaceutical composition for site-specific release of a clot-dissolving protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO951219D0 NO951219D0 (no) | 1995-03-30 |
| NO951219L true NO951219L (no) | 1995-06-06 |
Family
ID=19861342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO951219A NO951219L (no) | 1992-10-05 | 1995-03-30 | Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0662841B1 (de) |
| JP (1) | JPH08502060A (de) |
| AT (1) | ATE171073T1 (de) |
| AU (1) | AU5345494A (de) |
| CA (1) | CA2146324A1 (de) |
| DE (1) | DE69321131D1 (de) |
| NL (1) | NL9201722A (de) |
| NO (1) | NO951219L (de) |
| WO (1) | WO1994007537A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| US5968477A (en) | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| DE19529223A1 (de) * | 1995-08-09 | 1997-02-13 | Boehringer Mannheim Gmbh | Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau |
| JP7511916B2 (ja) * | 2019-04-12 | 2024-07-08 | ユージーエルケー サイエンス エービー | 腎臓を再調整するための方法および装置 |
| BR112021020423A2 (pt) * | 2019-04-12 | 2021-12-14 | Uglx Res Ab | Método e aparelho para recondicionar órgãos |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE831867A (fr) * | 1975-07-29 | 1976-01-29 | Association d'un activateur du plasminogene, d'une part, et du plasminogene lui-meme | |
| JPS52102975A (en) * | 1976-02-24 | 1977-08-29 | Toyota Motor Corp | Hydraulic driving system |
| US4193983A (en) * | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
| EP0227400B1 (de) * | 1985-12-16 | 1991-12-04 | Ethicon, Inc. | Hemmung von post-chirurgischer Adhäsionsbildung durch topische Verabreichung von Gewebeplasminogenaktivator |
| US5000960A (en) * | 1987-03-13 | 1991-03-19 | Micro-Pak, Inc. | Protein coupling to lipid vesicles |
| JP2764264B2 (ja) * | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
-
1992
- 1992-10-05 NL NL9201722A patent/NL9201722A/nl not_active Application Discontinuation
-
1993
- 1993-10-05 DE DE69321131T patent/DE69321131D1/de not_active Expired - Lifetime
- 1993-10-05 WO PCT/NL1993/000195 patent/WO1994007537A1/en not_active Ceased
- 1993-10-05 JP JP6508918A patent/JPH08502060A/ja active Pending
- 1993-10-05 EP EP93923685A patent/EP0662841B1/de not_active Expired - Lifetime
- 1993-10-05 AU AU53454/94A patent/AU5345494A/en not_active Abandoned
- 1993-10-05 AT AT93923685T patent/ATE171073T1/de active
- 1993-10-05 CA CA002146324A patent/CA2146324A1/en not_active Abandoned
-
1995
- 1995-03-30 NO NO951219A patent/NO951219L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0662841A1 (de) | 1995-07-19 |
| CA2146324A1 (en) | 1994-04-14 |
| DE69321131D1 (de) | 1998-10-22 |
| AU5345494A (en) | 1994-04-26 |
| NL9201722A (nl) | 1994-05-02 |
| EP0662841B1 (de) | 1998-09-16 |
| NO951219D0 (no) | 1995-03-30 |
| ATE171073T1 (de) | 1998-10-15 |
| JPH08502060A (ja) | 1996-03-05 |
| WO1994007537A1 (en) | 1994-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5025868B2 (ja) | 可逆的に不活性な酸性化プラスミン組成物の調製法 | |
| Björk et al. | The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin. | |
| Collen | Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent | |
| DE69015182T2 (de) | Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind. | |
| ATE279430T1 (de) | Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen | |
| EP0333740B1 (de) | Pharmazeutisch aktive konjugate mit spezifität für die bindung an körpergewebe | |
| HUT58812A (en) | Process for producing tissue plasminogen activator (t-pa) zimogenes and compositions containing them as active components | |
| US4902623A (en) | Plasminogen activator | |
| AU2036188A (en) | New tissue plasminogen activator | |
| ES2183805T3 (es) | Procedimiento de preparacion de un medicamento trombolitico. | |
| EP0355068A3 (de) | Rekombinante Hybrid-Immunoglobulin-Moleküle sowie deren Verwendung | |
| Bode et al. | Thrombolysis by a fibrin-specific antibody Fab′-urokinase conjugate | |
| NO951219L (no) | Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav | |
| Swenson et al. | α-Fibrinogenases | |
| US5747291A (en) | Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect | |
| RU2112528C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ФЕРМЕНТА ДЕСТАБИЛАЗЫ, ОБЛАДАЮЩЕГО ФИБРИНОЛИТИЧЕСКОЙ, ТРОМБОЛИТИЧЕСКОЙ, ЭНДО- И ЭКЗО- ε(γ GLY)-LYS-ИЗОПЕПТИДАЗНОЙ И АМИДОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ | |
| Tamura et al. | Purification of human plasma kallikrein and urokinase by affinity chromatography | |
| JPH0570607B2 (de) | ||
| Bachmann | Fibrinolytic agents | |
| ES2033295T3 (es) | Un metodo para preparar un activador de plasminogeno. | |
| Swenson et al. | Fibrolase | |
| Dewerchin et al. | Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin | |
| Suzuki et al. | A study on the properties of commercial thrombin preparations | |
| Yang et al. | Construction and expression of a recombinant antibody targeted plasminogen activator | |
| Matsuo | New thrombolytic agents: Basic development |